Status: Automated market-move research draft
DRREDDY • NSE • F&O Stock
DR. REDDY S LABORATORIES traded at ₹1,251.90, +2.53% versus the previous close of ₹1,221.00. Latest market data: 29 Sep 2026 • 03:15 PM IST.
- The stock is +2.53% at ₹1,251.90.
- Likely reason: Strong volume-backed momentum and sector outperformance
- Approximate traded value is ₹645.26 crore.
- It is -11.52% from its 52-week high and +13.71% from its 52-week low.
- The stock is being compared with Nifty Pharma alongside the Nifty 50.
DR. REDDY S LABORATORIES Share Price Today – Market Snapshot
Why Is DR. REDDY S LABORATORIES Share Price Rising Today?
Dr. Reddy's Laboratories shares advanced during the session, trading near the upper end of the day's range. The stock opened at ₹1,243.60 and touched a high of ₹1,251.90 before settling at ₹1,251.90, reflecting a gain of 2.53% over the previous close of ₹1,221.00. Trading volume was markedly robust, standing at over 2.08 times its 5-day average and more than 3.15 times its 20-day average, signaling elevated market participation.
The broader market sentiment was slightly negative, with the Nifty index slipping 0.28%. However, Dr. Reddy's outperformed both the broader market and its sector benchmark, Nifty Pharma, which posted a modest gain of 0.64%. The stock's positive momentum builds on a steady short-term recovery, adding to a 3.38% return over the past five sessions and a 6.91% gain over the last 20 sessions.
While the upward price movement coincides with ongoing operational updates—such as its recent exclusive distribution agreement with Takeda Biopharmaceuticals for Qdenga in India—no single fresh corporate catalyst was announced today. Consequently, the price action reflects a continuation of recent positive momentum supported by strong delivery volumes and sector-relative strength rather than a direct, newly disclosed corporate trigger.
low confidence
- Daily price gain of 2.53% with the stock closing near the day's high of ₹1,251.90
- Volume surging to 3.15x its 20-day average
- Outperformance against a weak Nifty index (-0.28%)
Performance Context
Cash-Market Activity
| Today’s Volume | 5,154,261 |
|---|---|
| 5-Day Avg. Volume | 2,479,893 |
| 20-Day Avg. Volume | 1,636,892 |
| Volume vs 20-Day Avg. | 3.15x |
| Delivery Quantity | 2,450,987 |
| Delivery % | 45.84% |
| Number of Trades | 116,376 |
Derivative-Market Activity
| Near-Month Futures | ₹1,224.10 |
|---|---|
| Cash Reference | ₹1,221.02 |
| Premium / Discount | ₹3.08 (+0.25%) |
| Change in Premium | ₹0.38 |
| Futures Volume | 8,029 |
| Volume vs Previous Session | 1.03x |
| Open Interest | 3,697,500 |
| OI vs Previous Session | 0.61x |
Ownership & Transaction Activity
Insider Activity – Recent NSE Disclosures
| Person | Category | Activity | Qty | Post Holding | Date |
|---|---|---|---|---|---|
| Patrick Aghanian | Insider / disclosed person | Buy | 3675 | 8450 | 26-Mar-2026 |
| Tricia Wetzel | Insider / disclosed person | Buy | 4275 | 4275 | 09-Dec-2025 |
Source: NSE PIT / insider disclosures. Transactions are factual disclosures and are not automatically directional signals.
WittyTrades Data Insight
Price Position: The stock is near the upper end of the day’s trading range.
Move From Open: +0.67%.
Intraday Range: 1.79% of the previous close.
5-Day Performance: +3.38%; 20-Day Performance: +6.91%.
Latest Company Developments
Relative Performance
| DR. REDDY S LABORATORIES | +2.53% |
|---|---|
| Nifty 50 | -0.28% |
| Nifty Pharma | +0.64% |
| Vs Nifty 50 | +2.81% |
| Vs Sector | +1.89% |
Technical Context
| Price | ₹1,251.90 |
|---|---|
| Day High / Low | ₹1,251.90 / ₹1,230.00 |
| 52-Week High | ₹1,414.90 |
| 52-Week Low | ₹1,101.00 |
| 5-Day Return | +3.38% |
| 20-Day Return | +6.91% |
What Should Traders and Investors Watch Next?
- Upcoming financial results for the quarter ending September 30, 2026, scheduled for October 23, 2026
- Sustained delivery volumes and open interest trends following significant futures unwinding
- Execution progress on recent distribution partnerships such as the Takeda Qdenga agreement
- Regulatory updates regarding pending product approvals and exchange clarifications
Catalyst note: No single confirmed corporate catalyst drove today's move; the advance reflects strong volume-backed momentum and outperformance against broader market weakness.
Frequently Asked Questions
What is the likely reason for today’s move?
The stock moved up 2.53% on heavy volume that was more than triple its 20-day average, outperforming a declining Nifty benchmark and gaining relative strength. Because no major new catalyst was released today, the move is best interpreted as continuation of recent positive momentum backed by strong market participation.
Is trading volume elevated?
Today’s volume is 5,154,261. The latest 20-day average available is 1,636,892, equivalent to about 3.15x of the recent average.
What does the derivatives market show?
The latest official NSE F&O report is summarised in the Derivative-Market Activity box above.
Before acting on this stock
Consult your own investment adviser before acting on any security. If you are interested in stock research or other available research categories, review the WittyTrades subscription plans and research segments.
Market data, exchange filings, company disclosures and reputable business-media reports are collected automatically and summarised for investor context. Material facts are cross-checked where possible; price data may be delayed and a cited development should not be assumed to be the sole cause of a market move unless the evidence supports that conclusion.
Article by: WittyTrades Research Desk
Investments in securities markets are subject to market risks. Read all related documents carefully before investing.
Registration granted by SEBI, membership of a supervisory body and certification from NISM do not guarantee performance of the intermediary or provide any assurance of returns to investors.
This article is intended for informational and educational purposes and should not be treated as personalised investment advice or a recommendation to buy, sell or hold any security.
Market data may be delayed and readers should independently verify current prices and disclosures before taking investment decisions.